

The Role of Azathioprine's for the prevention of Autoimmune Disorders

Dong Liu*

Department of Pharmacy, Huazhong University of Science and Technology, Hubei, Wuhan, China

DESCRIPTION

Azathioprine is a medication that has proven to be invaluable in the management of various autoimmune diseases. As an immunosuppressive agent, it plays a important role in modulating the immune system, making it a basis in the treatment of conditions such as rheumatoid arthritis, inflammatory bowel disease, and systemic lupus erythematosus. In this article, we will delve into the details of azathioprine, exploring its mechanism of action, therapeutic uses, potential side effects, and the importance of careful monitoring during its administration.

Mechanism of action

Azathioprine belongs to a class of medications known as immunosuppressants. It is a prodrug, meaning that it undergoes a series of transformations in the body to become its active form, 6-mercaptopurine. This active metabolite interferes with the synthesis of deoxyribonucleic acid and ribonucleic acid, particularly in rapidly dividing cells like those of the immune system. By disrupting the proliferation of immune cells, azathioprine suppresses the overactive immune response characteristic of autoimmune diseases [1,2].

Therapeutic uses

Rheumatoid arthritis: Azathioprine is often prescribed in combination with other Disease-Modifying Antirheumatic Drugs (DMARDs) for the management of rheumatoid arthritis. Its immunosuppressive properties help alleviate joint inflammation and slow down the progression of the disease [3].

Inflammatory Bowel Disease (IBD): Both Crohn's disease and ulcerative colitis, the two main forms of IBD, can be challenging to manage. Azathioprine is utilized as a maintenance therapy to reduce the frequency of flare-ups and sustain remission in these conditions [4,5].

Systemic Lupus Erythematosus (SLE): In SLE, the immune system mistakenly attacks healthy tissues throughout the body. Azathioprine is employed to suppress this autoimmune response, aiding in the control of symptoms and preventing organ damage [6].

Side effects and considerations

While azathioprine can be highly effective, it is not without potential side effects. Common adverse reactions include nausea, vomiting, and myelosuppression (a reduction in blood cell counts). Patients taking azathioprine must undergo regular blood tests to monitor for any signs of bone marrow suppression. Additionally, there is an increased risk of infections due to the medication's impact on the immune system [7].

Long-term use of azathioprine has been associated with a slightly elevated risk of certain cancers, particularly lymphomas. This risk should be carefully weighed against the benefits of the medication, and patients are often monitored closely for any signs of malignancy.

Pregnant women or those planning to conceive should consult their healthcare providers before taking azathioprine, as the medication may pose risks to the developing fetus [8].

Monitoring and patient education

Close monitoring is important during azathioprine therapy. Regular blood tests, including complete blood counts and liver function tests, help ensure that the medication is well-tolerated and does not lead to serious complications [9].

Patients must be educated about the importance of adherence to their prescribed regimen and the necessity of reporting any unusual symptoms promptly. This proactive approach allows healthcare providers to make necessary adjustments to the treatment plan, optimizing its efficacy while minimizing potential risks [10].

CONCLUSION

Azathioprine has emerged as a valuable tool in the management of autoimmune diseases, offering relief to countless individuals with conditions that can significantly impact their quality of life. While its immunosuppressive effects are potent, the careful balance between therapeutic benefits and potential risks must be

Correspondence to: Dong Liu, Department of Pharmacy, Huazhong University of Science and Technology, Hubei, Wuhan, China, E-mail: DongLi@2069.com

Received: 07-Nov-2023, Manuscript No. JPME-23-28126; **Editor assigned:** 09-Nov-2023, Pre QC No. JPME-23-28126 (PQ); **Reviewed:** 23-Nov-2023, QC No. JPME-23-28126; **Revised:** 30-Nov-2023, Manuscript No. JPME-23-28126 (R); **Published:** 07-Dec-2023, DOI: 10.35248/2684-1290.23.6.195.

Citation: Liu D (2023) The Role of Azathioprine's for the prevention of Autoimmune Disorders. J Perioper Med. 6:195.

Copyright: © 2023 Liu D. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

maintained through vigilant monitoring and patient education. As our understanding of autoimmune diseases and their treatment continues to evolve, azathioprine remains a key player in the arsenal of medications aimed at restoring balance to the immune system and improving the lives of those affected.

REFERENCES

1. Peppelenbosch MP, Van Deventer SJ. T cell apoptosis and inflammatory bowel disease. *Gut*. 2004;53(11):1556-1558.
2. Lintzeri DA, Constantinou A, Hillmann K, Ghoreschi K, Vogt A, Blume-Peytavi U. Alopecia areata—Current understanding and management. *Deutsch Dermatol Ges* 2022;20(1):59-90.
3. Ernste FC, Reed AM. Idiopathic inflammatory myopathies: Current trends in pathogenesis, clinical features, and up-to-date treatment recommendations. *Mayo Clin Proc* 2013;88(1):83-105.
4. Colaneri J. An overview of transplant immunosuppression-history, principles, and current practices in kidney transplantation. *Nephrol Nurs J*. 2014;41(6):549.
5. Quintero OL, Rojas-Villarraga A, Mantilla RD, Anaya JM. Autoimmune diseases in the intensive care unit. An update. *Autoimmun Rev* 2013;12(3):380-395.
6. Russell LA, Craig C, Flores EK, Wainaina JN, Keshock M, Kasten MJ, et al. Preoperative management of medications for rheumatologic and HIV Diseases: Society for Perioperative Assessment and Quality Improvement (SPAQI) consensus statement. *Mayo Clin Proc*. 2022;97(8):1551-71.
7. Mann A, Machado NM, Liu N, Mazin AH, Silver K, Afzal KI. A multidisciplinary approach to the treatment of anti-NMDA-receptor antibody encephalitis: A case and review of the literature. *J Neuropsychiatry Clin Neurosci* 2012;24(2):247-254.
8. Candotti F. Clinical manifestations and pathophysiological mechanisms of the Wiskott-Aldrich syndrome. *J Clin Immunol* 2018;38(1):13-27.
9. Buchbinder D, Nugent DJ, Phillipovich AH. Wiskott-Aldrich syndrome: Diagnosis, current management, and emerging treatments. *Appl Clin Genet*. 2014;7:55-66.
10. Tracey I, Dunckley P. Importance of anti-and pro-nociceptive mechanisms in human disease. *Gut*. 2004;53(11):1553-1555.